QT PRODACT: Evaluation of the Potential of Compounds to Cause QT Interval Prolongation by Action Potential Assays Using Guinea-Pig Papillary Muscles
Yoshihide Kii(Japan Medical Association), Keiji Yamamoto(RIKEN Center for Computational Science), Mitsuyasu Tabo(Japan Medical Association), Seiji Hayashi, Hajime Morimoto(Otsuka (Japan)), Toshiyasu Hombo(Astellas Pharma (Japan)), Shin-ichi Kitani(Japan Medical Association), Kazuo Kobayashi(Kyushu University), Toshimasa Ishitsuka(Japan Medical Association), Yuji Tsurubuchi(Japan Medical Association), Chieko Kasai(Astellas Pharma (Japan)), Shinya Taniguchi(Konan University), Takashi Shimosato, Atsuhiro Kanda(Hokkaido University), Hitoshi Fukuda, Shigekazu Shimizu(Japan Medical Association), Chiaki Shimada(Japan Medical Association), Masaharu Komeno(Japan Medical Association), Tetsuji Itoh(Merck & Co., Inc., Rahway, NJ, USA (United States)), Tatsuya Mori(Kyowa Kirin (Japan)), Kiyoshi Yamada(Japan Medical Association), Yoichi Kiuchi(Taisho Pharmaceutical (Japan)), H Amano(Mitsubishi Group (Japan)), Shun-ichi Yasuda(Japan Medical Association), Mamoru Saitō(Japan Medical Association), Takanobu Yamazaki(Kyorin University)
Cited by 20
Related Papers
Genetic variants near <i>TIMP3</i> and high-density lipoprotein–associated loci influence susceptibility to age-related macular degeneration
|Proceedings of the National Academy of Sciences|2010|518
Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial
|The Lancet. Gastroenterology & hepatology|2018|174
Olmesartan Is an Angiotensin II Receptor Blocker with an Inhibitory Effect on Angiotensin-Converting Enzyme
|Hypertension Research|2006|135